TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage immuno-oncology and RNA therapeutics company, has released updated clinical data from its Phase 1a trial of TTX-MC138 in patients with relapsed or refractory, unresectable locally advanced or metastatic solid tumors. The results, as of September 1, show that 10 of 14 efficacy-evaluable patients (71.4%) achieved stable disease as their best overall response. Six patients remained progression-free at three months, while three continued to be progression-free at six, nine, and 12 months. The disease control rate was 57.1% at Cycle 3 Day 1 and 35.7% at Cycle 6 Day 1.
A post-hoc Growth Modulation Index (GMI) analysis found that six of 15 evaluable patients (40%) achieved a GMI greater than 1.3, indicating a progression-free interval at least 30% longer than with their immediately preceding therapy. A total of 98 doses had been administered as of September 1, with no dose-limiting toxicities reported and no treatment-emergent adverse events leading to treatment discontinuation, including at the highest evaluated dose of 4.8 mg/kg. Exploratory RNA-sequencing analysis also identified treatment-associated immune effects that the company said support the observed clinical activity, although the small-sample biomarker findings require confirmation in larger studies.
TransCode is evaluating dose-expansion strategies and plans to continue assessing safety, pharmacokinetics, pharmacodynamics, and antitumor activity. The company’s lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. TransCode also has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
This news is significant for the oncology community and investors, as it suggests that TTX-MC138 may offer clinical benefit for patients with advanced solid tumors who have limited treatment options. The absence of dose-limiting toxicities and treatment discontinuations at the highest dose is particularly encouraging, indicating a favorable safety profile. If confirmed in larger trials, these findings could position TransCode as a key player in the development of RNA-based cancer therapies.
For more details, the full press release is available at https://ibn.fm/mIBZR, and the latest updates on RNAZ can be found in the company’s newsroom at https://ibn.fm/RNAZ. BioMedWire, a specialized communications platform for the biotech and life sciences sectors, originally distributed this announcement. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit BioMedWire or its disclaimer page at https://www.BioMedWire.com/Disclaimer.
